Vivodyne — Funding & Company Data

Vivodyne's funding trajectory shows a rapid and significant scaling of investor confidence. The initial $4 million seed round in 2021 provided the foundational capital to validate its technology, which originated from research at the University of Pennsylvania. The massive $38 million seed round in late 2023, led by the influential Khosla Ventures, marked a major inflection point, signaling that the company had demonstrated significant progress and potential.

The subsequent $40 million Series A in mid-2025, again led by Khosla Ventures, solidifies Vivodyne's position as a well-capitalized player in the biotech space. This level of funding is critical in a capital-intensive field that combines robotics, AI, and bioengineering. The consistent support from its lead investor and the addition of new institutional backers suggest a strong belief in the company's ability to address the high failure rate of drugs that pass animal trials but fail in human ones.

This capital provides a long runway to scale its operations, evidenced by plans to open a new 23,000-square-foot robotic lab in San Francisco. From a competitive standpoint, this funding allows Vivodyne to build a significant moat by generating massive, proprietary datasets from its human tissue models. This data is the fuel for its AI platform, creating a virtuous cycle where more data leads to better predictions, attracting more pharmaceutical partners and further solidifying its market position against competitors.